Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123I]β-CIT SPECT study

European Neuropsychopharmacology

Volumn 25, Issue 6, 2015, Pages 873-881

  Rominger, A ^a   Cumming, P ^b   Brendel, M ^a   Xiong, G ^a   Zach, C ^a   Karch, S ^a   Tatsch, K ^c   Bartenstein, P ^a   la Fougere C ^d   Koch, W ^a   Pogarell, O ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OSLO   (Norway)

^c Municipal Hospital of Karlsruhe Inc   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

DAT; Escitalopram; Major depressive disorder; SERT; SPECT; 123I CIT

Indexed keywords

DOPAMINE TRANSPORTER; ESCITALOPRAM; IOMETOPANE I 123; SEROTONIN TRANSPORTER; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN; TROPANE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS; BRAIN; DEPRESSION; DRUG EFFECTS; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; STATISTICS; YOUNG ADULT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BRAIN; CITALOPRAM; DEPRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; STATISTICS AS TOPIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; YOUNG ADULT;

EID: 84930276080     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.12.010     Document Type: Article

References (51)

1. 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J. Nucl. Med. 2007, 48:359-366.
2. 123I]beta-CIT. Binding kinetics in the human brain. J. Neural. Transm. Gen. Sect. 1993, 94:137-146.
3. 123I-ADAM SPECT study. Psychopharmacology (Berl) 2006, 189:145-153.
4. Clark R.N., Ashby C.R., Dewey S.L., Ramachandran P.V., Strecker R.E. Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse 1996, 23:125-131.
5. Conway C.R., Chibnall J.T., Cumming P., Mintun M.A., Gebara M.A., Perantie D.C., Price J.L., Cornell M.E., McConathy J.E., Gangwani S., Sheline Y.I. Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study. Psychiatry Res. 2014, 221:231-239.
6. Cumming P. Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review. Synapse 2011, 65:892-909.
7. Cumming P., Gjedde A. Kinetics of the uptake of [3H]paroxetine in the rat brain. Synapse 1993, 15:124-129.
8. De Keyser J., De Backer J.P., Ebinger G., Vauquelin G. [3H]GBR 12935 binding to dopamine uptake sites in the human brain. J. Neurochem. 1989, 53:1400-1404.
9. Desmyter S., van Heeringen C., Audenaert K. Structural and functional neuroimaging studies of the suicidal brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:796-808.
10. Dewar K.M., Grondin L., Nenonene E.K., Ohayon M., Reader T.A. [3H]paroxetine binding and serotonin content of rat brain: absence of changes following antidepressant treatments. Eur. J. Pharmacol. 1993, 235:137-142.
11. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., Ashby C.R. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J. Neurosci. 1995, 15:821-829.
12. 123I]epidepride: resolving conflicting findings. NeuroImage 2003, 19:1205-1214.
13. Ersche K.D., Cumming P., Craig K.J., Muller U., Fineberg N.A., Bullmore E.T., Robbins T.W. Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?. J. Psychopharmacol. 2012, 26:887-890.
14. Gryglewski G., Lanzenberger R., Kranz G.S., Cumming P. Meta-analysis of molecular imaging of serotonin transporters in major depression. J. Cereb. Blood Flow Metab. 2014, 34:1096-1103.
15. Haddad P.M. Antidepressant discontinuation syndromes. Drug Saf. 2001, 24:183-197.
16. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 1994, 9(Suppl 1):19-26.
17. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 2002, 27:949-959.
18. Kovacevic T., Skelin I., Diksic M. Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats. Synapse 2010, 64:231-240.
19. Kugaya A., Seneca N.M., Snyder P.J., Williams S.A., Malison R.T., Baldwin R.M., Seibyl J.P., Innis R.B. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003, 28:413-420.
20. Kuikka J.T., Tammela L., Bergstrom K.A., Karhunen L., Uusitupa M., Tiihonen J. Effects of ageing on serotonin transporters in healthy females. Eur. J. Nucl. Med. 2001, 28:911-913.
21. Kuikka J.T., Tupala E., Bergstrom K.A., Hiltunen J., Tiihonen J. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects. Eur. J. Nucl. Med. 1999, 26:1486-1488.
22. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993, 13:295-309.
23. Laruelle M., Vanisberg M.A., Maloteaux J.M. Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites. Biol. Psychiatry 1988, 24:299-309.
24. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J. Cereb. Blood Flow Metab. 1994, 14:982-994.
25. Lau, T., Horschitz, S., Berger, S., Bartsch, D. Schloss, P. (2008) Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons. FASEB J.: Official Publication of the Federation of American Societies for Experimental Biology, 22, 1702-1714.
26. Leroy C., Comtat C., Trebossen R., Syrota A., Martinot J.L., Ribeiro M.J. Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J. Nucl. Med. 2007, 48:538-546.
27. Lipinski J.F., Mallya G., Zimmerman P., Pope H.G. Fluoxetine-induced akathisia: clinical and theoretical implications. J. Clin. Psychiatry 1989, 50:339-342.
28. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. NeuroImage 2003, 19:1233-1239.
29. 123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol. Psychiatry 1998, 44:1090-1098.
30. Mash D.C., Pablo J., Ouyang Q., Hearn W.L., Izenwasser S. Dopamine transport function is elevated in cocaine users. J. Neurochem. 2002, 81:292-300.
31. Nikolaus S., Antke C., Muller H.W. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav. Brain Res. 2009, 204:32-66.
32. Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., Brucke T. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 2000, 41:36-44.
33. Pogarell O., Poepperl G., Mulert C., Hamann C., Sadowsky N., Riedel M., Moeller H.J., Hegerl U., Tatsch K. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur. Neuropsychopharmacol. 2005, 15:521-524.
34. Rao N. The clinical pharmacokinetics of escitalopram. Clin. Pharmacokinet. 2007, 46:281-290.
35. 123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:841-849.
36. Ruhe H.G., Ooteman W., Booij J., Michel M.C., Moeton M., Baas F., Schene A.H. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet. Genomics 2009, 19:67-76.
37. Ryding E., Lindstrom M., Bradvik B., Grabowski M., Bosson P., Traskman-Bendz L., Rosen I. A new model for separation between brain dopamine and serotonin transporters in 123I-beta-CIT SPECT measurements: normal values and sex and age dependence. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:1114-1118.
38. Schatzberg A.F. New indications for antidepressants. J. Clin. Psychiatry 2000, 61(Suppl 11):9-17.
39. Scheffel U., Kim S., Cline E.J., Kuhar M.J. Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: in vivo studies with [125I]RTI-55. Synapse 1994, 16:263-268.
40. 123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J. Clin. Psychopharmacol. 2007, 27:71-75.
41. Smith G.S., Ma Y., Dhawan V., Chaly T., Eidelberg D. Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. Synapse 2009, 63:1-6.
42. Staley J.K., Basile M., Flynn D.D., Mash D.C. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [125I]RTI-55: in vitro binding and autoradiographic characterization. J. Neurochem. 1994, 62:549-556.
43. 123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001, 41:275-284.
44. Tauscher J., Pirker W., de Zwaan M., Asenbaum S., Brucke T., Kasper S. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur. Neuropsychopharmacol. 1999, 9:177-179.
45. 123)I]beta-CIT SPECT. Neurobiol. Aging 2000, 21:497-501.
46. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Wallace E., Zoghbi S.S., Zea-Ponce Y., Baldwin R.M., Charney D.S., Hoffer P.B. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J. Nucl. Med. 1995, 36:1175-1181.
47. Vernaleken I., Janouschek H., Raptis M., Hellmann S., Veselinovic T., Brocheler A., Boy C., Cumming P., Hiemke C., Rosch F., Schafer W.M., Grunder G. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int. J. Neuropsychopharmacol. 2010, 13:951-960.
48. Vollenweider F.X., Vontobel P., Hell D., Leenders K.L. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man-a PET study with [11C]raclopride. Neuropsychopharmacology 1999, 20:424-433.
49. Wittchen H.U., Zaudig M., Frydrich T. SKID-Strukturiertes Klinisches Interview Für DSM IV. Achse I and II: Handanweisungen 1997, Hogrefe Verlag, Göttingen, Germany.
50. Ziebell M., Holm-Hansen S., Thomsen G., Wagner A., Jensen P., Pinborg L.H., Knudsen G.M. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J. Nucl. Med. 2010, 51:1885-1891.
51. Zitterl W., Stompe T., Aigner M., Zitterl-Eglseer K., Ritter K., Zettinig G., Hornik K., Asenbaum S., Pirker W., Thau K. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. Biol. Psychiatry 2009, 66:1115-1122.